Compare BNR & HRZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BNR | HRZN |
|---|---|---|
| Founded | 2014 | 2008 |
| Country | China | United States |
| Employees | 674 | N/A |
| Industry | Medical Specialities | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 252.7M | 295.1M |
| IPO Year | 2019 | N/A |
| Metric | BNR | HRZN |
|---|---|---|
| Price | $22.81 | $4.24 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $6.80 |
| AVG Volume (30 Days) | 13.1K | ★ 1.4M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | ★ 30.99% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $136.32 | $19.99 |
| Revenue Next Year | N/A | $27.95 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.18 | $4.00 |
| 52 Week High | $41.72 | $9.52 |
| Indicator | BNR | HRZN |
|---|---|---|
| Relative Strength Index (RSI) | 40.95 | 17.25 |
| Support Level | $7.99 | N/A |
| Resistance Level | $24.23 | $6.81 |
| Average True Range (ATR) | 2.07 | 0.25 |
| MACD | -0.41 | -0.21 |
| Stochastic Oscillator | 29.88 | 9.57 |
Burning Rock Biotech Ltd is a cancer diagnostics company. It is a NGS-based cancer therapy selection company. Its cancer therapy selection platform is built upon advanced proprietary technologies, comprehensive portfolio of products and a two-pronged market-driven commercial infrastructure addressing both larger hospitals through company's in-hospital model and smaller hospitals through its central laboratory model. It had three operating segments, including Central laboratory business, In-hospital business and Pharma research and development services. It generates the majority of its revenue from Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, brPROPHET, OncoScreen Plus, and others.
Horizon Technology Finance Corp is a specialty finance company. Its investment objective is to maximize its investment portfolio's total return by generating current income from the debt investments it makes and capital appreciation from the warrants it receives when making such debt investments. It lends to and invests in development-stage companies in the technology, life science, healthcare information and services, and sustainability industries.